Stay updated with breaking news from Cancer Theranostics Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today
SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to...
AT-01 is the first pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosisAT-01 visualizes and quantifies organ-specific...
Final Phase 1/2 Study Results for AT-01 (Evuzamitide), Attralus's Novel Pan-Amyloid Imaging Agent for the Detection of Systemic Amyloidosis Repeat PET/CT...
Final Phase 1/2 Study Results for AT-01 (Evuzamitide), Attralus's Novel Pan-Amyloid Imaging Agent for the Detection of Systemic Amyloidosis Repeat PET/CT...